Are Thrombotic Events in Antineutrophil Cytoplasmic Antibody–associated Vasculitis Related to the Effect of Antiphospholipid Antibodies?

To the Editor:

The high incidence of thrombotic phenomenon among individuals with antineutrophil cytoplasmic antibody–associated vasculitis (AAV) was the subject of an intriguing article by Kang, et al. The reported susceptibility to both arterial and venous thrombotic events is also uniquely characteristic of the antiphospholipid syndrome. Similarly, a possible explanation for thrombotic events in AAV may be modulation of platelet function by antiphospholipid antibodies (aPL). Given the similarities between the 2 phenomena, it would seem reasonable to assess presence of aPL, at least in AAV patients with thrombotic events, if not in all individuals with AAV, and to act prophylactically in the latter group. This is especially pertinent for those with thrombotic events, because presence of aPL requires modification of standard intervention. Which antibodies to test for? I suggest IgG, IgM, and IgA antibodies to anticardiolipin, β2-glycoprotein I, and antiphosphatidylserine/prothrombin.

If aPL are present, use of aspirin or a cyclooxygenase 1-predominant nonsteroidal antiinflammatory drug (NSAID) might be considered. While use of low-dose aspirin for primary prevention of antiphospholipid complications has been a matter for debate, there is an explanation for the confusion. It arises from the assumption that standard aspirin dosing (< 100 mg/day) is a valid approach. There is significant variation in aspirin’s clinical efficacy as an inhibitor of platelet function. As high a dose as 1000 mg per day may be required and even that may not be effective. Simply prescribing aspirin or an NSAID, without assessing efficacy as an inhibitor of platelet function and compliance, is inadequate. Platelet function testing (of response to epinephrine and collagen) is essential. Failure to produce response time prolongation (interference with platelet function) identifies inadequate efficacy. If anticoagulation intervention is alternatively chosen, the options are unfractionated heparin or high-dose warfarin (3.0–3.5 international normalized ratio). Unfortunately, the very convenient fractionated heparins have been ineffective in preventing further thrombotic events in individuals with antiphospholipid syndrome.

BRUCE M. ROTHSCHILD, MD, Indiana University School of Medicine, Muncie, Indiana, USA. Address correspondence to Dr. B.M. Rothschild, 2401 W. University Ave., Muncie, Indiana 47303, USA. E-mail: spondylair@gmail.com

REFERENCES


First Release June 1 2019; J Rheumatol 2019;46:7; doi:10.3899/jrheum.190358